Stock CELLADON CORP
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Celladon Corp Nasdaq

Equities

US15117E1073

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist with FDA Breakthrough Therapy Designation
AQ
Amylyx Pharmaceuticals Acquires Avexitide From Eiger BioPharmaceuticals for $35 Million
MT
Spruce Biosciences, Inc. completed the acquisition of Substantially all of rights, title, interests, assets in Avexitide of Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $10 million.
CI
Moshe Arkin Engages with Eiger BioPharmaceuticals
CI
Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar
RE
Spruce Biosciences, Inc. stalking horse asset purchase agreement to acquire Substantially all of rights, title, interests, assets in Avexitide of Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $10 million.
CI
Sentynl Therapeutics, Inc. acquired Global rights to Zokinvy Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $45.2 million.
CI
Sentynl Therapeutics Announces Global Acquisition of Zokinvy for Treatment of Hutchinson-Gilford Progeria Syndrome from Eiger BioPharmaceuticals
AQ
Zydus Lifesciences Arm Acquires Eiger BioPharmaceuticals' Progeria Drug
MT
Eiger Biopharmaceuticals, Inc. Announces Resignation of William G. Kachioff as Chief Financial Officer
CI
Eiger Biopharmaceuticals, Inc. Appoints Douglas Staut to Serve as the Company's Chief Restructuring Officer
CI
Motion for Asset Sale Approved for Eiger BioPharmaceuticals, Inc.
CI
Selection of Successful Bidder Filed by Eiger BioPharmaceuticals, Inc.
CI
Eiger BioPharmaceuticals, Inc.(NasdaqGM:EIGR) dropped from NASDAQ Composite Index
CI
Eiger BioPharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Bidding Procedure Approved for Eiger BioPharmaceuticals, Inc.
CI
Motion for Joint Administration Approved for Eiger BioPharmaceuticals, Inc.
CI
Eiger BioPharmaceuticals, Inc.(NasdaqGM:EIGR) dropped from S&P TMI Index
CI
Eiger BioPharmaceuticals, Inc. Announces Resignation of Jeffrey S. Glenn as Member of the Board of Directors
CI
Health Care Down as Obesity-Drug Optimism Fades -- Health Care Roundup
DJ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EIGR Stock
  4. Stock
  5. News Celladon Corp